United Therapeutics (UTHR) Interest Coverage Ratio Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Interest Coverage Ratio Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 17.76% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -38.91% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -63.37% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 93.04% |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 34.31% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 128.45% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 128.45% |
| Mar 31, 2026 | 73.06% |
| Dec 31, 2025 | 154.13% |
| Sep 30, 2025 | 281.22% |
| Jun 30, 2025 | 81.06% |
| Mar 31, 2025 | 134.25% |
| Dec 31, 2024 | 162.86% |
| Sep 30, 2024 | 62.06% |
| Jun 30, 2024 | 30.23% |
| Mar 31, 2024 | 29.99% |
| Dec 31, 2023 | 20.65% |
| Sep 30, 2023 | -38.64% |
| Jun 30, 2023 | -34.94% |
| Mar 31, 2023 | -66.37% |
| Dec 31, 2022 | -60.48% |
| Sep 30, 2022 | -31.29% |
| Jun 30, 2022 | -31.15% |
| Mar 31, 2022 | 534.99% |
| Dec 31, 2021 | 165.56% |
| Sep 30, 2021 | 10.18% |